FORWARD-LOOKING STATEMENTS In this Quarterly Report on Form 10-Q (Quarterly Report), Labcorp® Holdings Inc. together with its subsidiaries (Labcorp, LHI or the Company) has made, and from time to time may otherwise make in its public filings, press releases, and discussions by Company management, forward-looking statements concerning the Company’s operations, performance, and financial condition, as well as its strategic objectives. Some of these forward-looking statements relate to future events and expectations and can be identified by the use of forward-looking words such as “believes”, “expects”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates”, or “anticipates” or the negative of those words or other comparable terminology. Such forward-looking statements speak only as of the time they are made and are subject to various risks and uncertainties and the Company claims the protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those currently anticipated due to a number of factors in addition to those discussed elsewhere herein, including in the “Risk Factors” section of the Annual Report, and in the Company’s other public filings, press releases, and discussions with Company management, including: 1.changes in government and third-party payer regulations, reimbursement, or coverage policies or other future reforms in the U.S. healthcare system (or in the interpretation of current regulations), new insurance or payment systems, including state, regional or private insurance cooperatives (e.g., health insurance exchanges) affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of the U.S. Protecting Access to Medicare Act; 2.significant monetary damages, and penalties, and/or exclusion from or ineligibility to participate in government programs, among other adverse consequences, arising from enforcement of anti-fraud and abuse laws and other laws applicable to the Company in jurisdictions in which the Company conducts business; 3.significant fines, penalties, costs, unanticipated compliance expenditures, and/or damage to the Company’s reputation arising from the failure to comply with applicable privacy and security laws and regulations; 4.loss or suspension of a license or imposition of fines or penalties under, or future changes in or interpretations of the U.S. Clinical Laboratory Improvement Amendments of 1988, Medicare, Medicaid, or other national, state, or local laws or regulations of the U.S. and other countries where the Company operates laboratories; 5.penalties or loss of license arising from the failure to comply with applicable occupational and workplace safety laws and regulations, including the U.S. Occupational Safety and Health Administration requirements, the U.S. Needlestick Safety and Prevention Act, and similar laws and regulations in jurisdictions in which the Company conducts business; 6.fines, unanticipated compliance expenditures, suspension of manufacturing, enforcement actions, damage to the Company’s reputation, injunctions, or criminal prosecution arising from failure to maintain compliance with Current Good Manufacturing Practice regulations and similar requirements of various regulatory agencies in jurisdictions in which the Company conducts business; 7.sanctions or other remedies, including fines, unanticipated compliance expenditures, enforcement actions, injunctions or criminal prosecution arising from failure to comply with the U.S. Animal Welfare Act or applicable national, state, and local laws and regulations in jurisdictions in which the Company conducts business; 8.changes in testing guidelines or recommendations by government agencies, medical specialty societies, and other authoritative bodies affecting the development, validation, approval, clearance, commercialization, or utilization of laboratory tests; 9.changes in and failure to comply with the applicable regulations of pharmaceutical and medical device regulators affecting the approval, availability of, and the selling and marketing of diagnostic tests, including laboratory-developed tests, drug development, or the conduct of drug development and medical device and diagnostic studies and trials, including regulations and policies of the U.S. Food and Drug Administration, the U.S. Department of Agriculture, the Medicines and Healthcare Products Regulatory Agency in the U.K., the National Medical Products Administration in China, the Pharmaceutical and Medical Devices Agency in Japan, the European Union, the European Medicines Agency, and similar regulations and policies of agencies in other jurisdictions in which the Company conducts business; 10.changes in government regulations pertaining to the pharmaceutical, biotechnology, medical device, and diagnostic industries, changes in reimbursement of pharmaceutical products, or reduced spending on research and development by pharmaceutical, biotechnology, medical device, and diagnostic customers; 11.liabilities that result from the failure to comply with corporate governance requirements; 12.increased competition, including price competition, potential reduction in rates in response to price transparency initiatives and consumerism, competitive bidding and/or changes or reductions to fee schedules, and competition from companies that do not comply with existing applicable laws or regulations or otherwise disregard compliance standards in the industry; 13.changes in payer mix or payment structure or process, including insurance carrier participation in health insurance exchanges, an increase in capitated reimbursement mechanisms, the impact of clearinghouses on the claims reimbursement 24 TABLE OF CONTENTS process, the impact of a shift to consumer-driven health plans or plans carrying an increased level of member cost-sharing, and adverse changes in payer reimbursement or payer coverage policies (implemented directly or through a third-party utilization management organization) related to specific diagnostic tests, categories of testing, or testing methodologies; 14.failure to retain or attract business from MCOs as a result of changes in strategy or business models; 15.failure to obtain and retain new customers, an unfavorable change in the mix of testing services ordered, or a reduction in tests ordered, specimens submitted, or services requested by existing customers, and delays in payments from customers; 16.consolidation and convergence of customers, competitors, and suppliers, potentially causing material shifts in insourcing, utilization, pricing, reimbursement, and supply chain access; 17.failure to invest in or effectively develop and deploy new systems, system modifications or enhancements required in response to evolving market, business, and customer trends and needs; 18.failure to identify, successfully close, and effectively integrate and/or manage acquisitions of new businesses or failure to maintain key customers and/or employees as a result of uncertainty surrounding the integration of acquisitions; 19.inability to achieve the expected benefits and synergies of newly acquired businesses, including due to items not discovered in the due diligence process, and the impact on the Company’s cash position, levels of indebtedness, and stock price; 20.termination, loss, delay, reduction in scope, or increased costs of contracts; 21.liability arising from errors or omissions in the performance of testing and other services or other contractual arrangements; 22.changes or disruption in the provision or transportation of services or supplies provided by third parties; or their termination for failure to follow the Company’s performance standards and requirements; 23.damage or disruption to the Company’s facilities; 24.impact on the Company’s reputation, or business, from acts of animal rights activists or potential harm, liability, or operational disruptions arising from, or increased regulations and restrictions, of animal research activities; 25.adverse results in litigation matters; 26.inability to attract, retain, and develop experienced and qualified personnel, including personnel in key roles and critical positions, due to increased competition for talent, wage growth, or other market factors beyond the Company’s control; 27.failure to develop or acquire licenses for new or improved technologies, such as point-of-care testing, mobile health technologies, and digital pathology, or potential use of new technologies by customers and/or consumers to perform their own tests; 28.substantial costs arising from the inability to commercialize newly licensed tests or technologies or to obtain appropriate coverage or reimbursement for such tests; 29.failure to obtain, maintain, and enforce intellectual property rights for protection of the Company’s offerings and defend against challenges to those rights; 30.scope, validity, and enforceability of patents and other proprietary rights held by third parties that may impact the Company’s ability to develop, perform, or market the Company’s offerings or operate its business; 31.business interruption, receivables impairment, delays in cash collection impacting days sales outstanding, supply chain disruptions or inventory obsolescence, increases in the Company’s material costs or other operating costs, or other impacts on the business due to natural disasters, adverse weather, geopolitical events, public health crises, and other events beyond the Company’s control; 32.discontinuation or recalls of existing products used in the performance of testing; 33.a failure in the information technology systems of the Company or newly-acquired businesses, the failure of the Company or its third-party suppliers and vendors to maintain the security of their information technology systems or to protect against cybersecurity incidents, failures in the development and implementation of the Company’s automation platforms, or adverse effects from the use of or regulation of artificial intelligence and machine learning tools; 34.business interruption, increased costs, and other adverse effects on the Company’s operations due to the unionization of employees, union strikes, work stoppages, general labor unrest, or failure to comply with labor or employment laws; 35.failure to maintain the Company’s days sales outstanding levels, cash collections (in light of increasing levels of patient responsibility), profitability and/or reimbursement arising from unfavorable changes in third-party payer policies, payment delays introduced by third-party utilization management organizations, and increasing levels of patient payment responsibility; 36.impact on the Company’s revenues, cash collections, and the availability of credit for general liquidity or other financing needs arising from a significant deterioration in the economy or financial markets or in the Company’s credit ratings by S&P and/or Moody’s; 37.failure to maintain the expected capital structure for the Company, including failure to maintain the Company’s investment grade rating, or leverage ratio covenants under its revolving credit facility; 38.changes in reimbursement by foreign governments and foreign currency fluctuations; 39.inability to obtain certain billing information from physicians, resulting in increased costs and complexity, a temporary disruption in receipts, and ongoing reductions in reimbursements and revenues; 40.expenses and risks associated with international operations, including, but not limited to, compliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, other applicable anti-corruption laws and regulations, trade sanction laws and regulations, and economic, political, legal, and other operational risks associated with foreign jurisdictions; 25 TABLE OF CONTENTS 41.failure to achieve expected efficiencies, benefits, and savings in connection with the Company’s business process improvement initiatives; 42.changes in tax laws and regulations or changes in their interpretation; 43.changing global economic conditions and government and regulatory changes; and 44.risks associated with the impacts and expected benefits and costs of the completed Spin-off of the Company’s former clinical development and commercialization services business, Fortrea, including but not limited to factors that could adversely affect the Company’s ability to realize the expected benefits of the Spin-off or the failure of the Spin-off to qualify as a tax-free transaction for U.S. federal income tax purposes. Except as may be required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Given these uncertainties, one should not put undue reliance on any forward-looking statement. GENERAL (dollars in millions) For the three months ended June 30, 2026, the Company’s revenues were $3,731.1, an increase of 5.8% from $3,527.3 for the corresponding period in 2025. The 5.8% increase for the three months ended June 30, 2026, as compared to the corresponding period in 2025, was primarily due to organic revenue of 4.2%, acquisitions, net of divestitures, of 1.2%, and favorable foreign currency translation of 0.4%. For the six months ended June 30, 2026, the Company’s revenues were $7,268.7, an increase of 5.8% from $6,872.4 for the corresponding period in 2025. The 5.8% increase for the six months ended June 30, 2026, as compared to the corresponding period in 2025, was due to organic revenue of 3.6%, acquisitions, net of divestitures, of 1.3%, and favorable foreign currency translation of 0.9%. The Company defines organic revenue and organic growth as the increase in revenues excluding the year-over-year impact of acquisitions, divestitures, and currency, as well as other strategic actions taken in ED. The impacts relating to acquisitions, divestitures, and other strategic actions are considered for a 12-month period following the closing of each transaction. On July 4, 2025, the U.S. government enacted the OBBBA, which included provisions addressing regulations and federal funding affecting healthcare. These provisions include, but are not limited to, changes to Medicaid and the Affordable Care Act, and could lead to revised regulatory requirements and reduced federal funding. As a result of these changes, the Company could experience a decline in utilization of its diagnostics testing services due to a reduction in overall insurance coverage, which may cause the Company’s revenue to decrease. However, the Company currently believes any such reduction would not likely have a material impact on its results of operations in future periods. The potential impacts described above represent the Company’s assessment at this time, and the Company will continue to evaluate the impact of the OBBBA on its business and operations as the legislation’s provisions continue to become effective through 2028. RESULTS OF OPERATIONS (dollars in millions) The following tables present the financial measures that management considers to be the most significant indicators of the Company’s performance. Revenues Three Months Ended June 30, 2026 2025 Change Dx $ 2,900.7 $ 2,748.8 5.5 % BLS 836.2 784.8 6.5 % Intercompany eliminations and other (5.8) (6.3) (11.5) % Total $ 3,731.1 $ 3,527.3 5.8 % Dx revenues for the three months ended June 30, 2026, were $2,900.7, an increase of 5.5% over $2,748.8 in the second quarter of 2025. The increase was primarily due to organic revenue of 3.6% and acquisitions, net of divestitures, of 1.9%. Dx total volume, measured by requisitions, increased by 3.0% as organic volume increased by 1.8% and acquisition volume, net of divestitures, contributed 1.3%. Price/mix increased by 2.5% due to organic growth of 1.8% and acquisitions, net of divestitures, of 0.6%. BLS revenues for the three months ended June 30, 2026, were $836.2, an increase of 6.5% over $784.8 in the second quarter of 2025. The increase was due to organic growth of 6.2% and favorable foreign currency translation of 1.8%, partially offset by an unfavorable impact related to strategic actions undertaken in ED of 1.4%. 26 TABLE OF CONTENTS Cost of Revenues Three Months Ended June 30, 2026 2025 Change Cost of revenues $ 2,619.1 $ 2,481.1 5.6 % Cost of revenues as a percentage of revenues 70.2 % 70.3 % Cost of revenues increased 5.6% during the three months ended June 30, 2026, as compared with the corresponding period in 2025. Cost of revenues as a percentage of revenues during the three months ended June 30, 2026, decreased to 70.2% as compared to 70.3% in the corresponding period in 2025. This decrease was primarily due to organic growth and operating efficiencies, partially offset by increased personnel costs. Selling, General, and Administrative Expenses Three Months Ended June 30, 2026 2025 Change SG&A $ 577.2 $ 579.3 (0.3) % SG&A as a percentage of revenues 15.5 % 16.4 % SG&A as a percentage of revenues were 15.5% and 16.4% during the three months ended June 30, 2026, and 2025, respectively. The decrease was primarily due to revenue growth. Amortization of Intangibles and Other Assets Three Months Ended June 30, 2026 2025 Change Amortization of intangibles and other assets $ 78.1 $ 68.3 14.3 % The increase in amortization of intangibles and other assets primarily reflects additional amortization for assets acquired subsequent to June 30, 2025. Restructuring and Other Charges Three Months Ended June 30, 2026 2025 Change Restructuring and other charges $ 5.1 $ 4.1 21.2 % During the three months ended June 30, 2026, the Company recorded net restructuring and other charges of $5.1. The charges were comprised of $5.2 related to severance and other personnel costs, $1.7 in facility-related costs, and $0.1 in contract termination costs. The charges were adjusted by the reversal of previously established liabilities of $1.8 in unused facility-related costs and $0.1 in unused severance and other personnel costs. During the three months ended June 30, 2025, the Company recorded net restructuring and other charges of $4.1. The charges were comprised of $15.1 in contract termination costs, $9.4 related to severance and other personnel costs, and $7.3 in facility-related costs. The charges were adjusted by the reversal of previously established liabilities of $26.4 in unused facility-related costs and $1.3 in unused severance and other personnel costs. Interest Expense Three Months Ended June 30, 2026 2025 Change Interest expense $ 61.1 $ 57.1 6.9 % For the three months ended June 30, 2026, interest expense increased 6.9%, as compared with the corresponding period in 2025. The increase was primarily due to a higher average amount of total debt outstanding during the three months ended June 30, 2026, when compared to the three months ended June 30, 2025. Equity Method Loss, Net Three Months Ended June 30, 2026 2025 Change Equity method loss, net $ (6.2) $ (1.7) 259.6 % Equity method loss, net represents the Company’s ownership share in joint venture partnerships along with equity investments in other companies in the healthcare industry. The increase in Equity method loss, net for the three months ended June 30, 2026, as compared with the corresponding period in 2025, was primarily due to the loss recognized from the SYNLAB investment. 27 TABLE OF CONTENTS Other, Net Three Months Ended June 30, 2026 2025 Change Other, net $ (3.5) $ (32.7) (88.9) % The change in Other, net was primarily due to a decrease in investment losses recorded during the three months ended June 30, 2026, as compared to the corresponding period of 2025. Provision for Income Taxes Three Months Ended June 30, 2026 2025 Provision for income taxes $ 87.3 $ 66.4 Provision for income taxes as a percentage of earnings from operations before income taxes 22.6 % 21.8 % The increase in the effective tax rate for the three months ended June 30, 2026, as compared with the corresponding period in 2025, was primarily attributable to the jurisdictional mix of earnings. Operating Results by Segment Three Months Ended June 30, 2026 2025 Change Dx segment operating income $ 522.6 $ 482.8 8.2 % Dx segment operating margin 18.0 % 17.6 % 0.5 % (1) BLS segment operating income 142.2 123.3 15.3 % BLS segment operating margin 17.0 % 15.7 % 1.3 % Segment operating income 664.8 606.1 9.7 % General corporate and unallocated expenses (130.0) (139.2) (6.6) % Amortization of intangibles and other assets (78.1) (68.3) 14.3 % Restructuring and other charges (5.1) (4.1) 21.2 % Total Operating income $ 451.6 $ 394.5 14.5 % (1)Amount does not cross-foot due to rounding. Dx segment operating income was $522.6 for the three months ended June 30, 2026, an increase of $39.8 over operating income of $482.8 in the corresponding period of 2025, and Dx segment operating margin increased approximately 50 basis points year-over-year. The increase in operating income and operating margin was due to organic growth and operating efficiencies. BLS segment operating income was $142.2 for the three months ended June 30, 2026, an increase of $18.9 over operating income of $123.3 in the corresponding period of 2025, and BLS segment operating margin increased approximately 130 basis points year-over-year. The increase in operating income and operating margin was primarily due to organic growth in the Central Laboratory business and operating efficiencies from the strategic actions taken in ED. General corporate and unallocated expenses are comprised primarily of administrative services such as executive management, human resources, legal, finance, corporate affairs, and information technology. General corporate and unallocated expenses were $130.0 for the three months ended June 30, 2026, a decrease of $9.2 compared to general corporate and unallocated expenses of $139.2 in the corresponding period of 2025, primarily due to lower LaunchPad costs and other expenses, partially offset by higher acquisition and disposition-related costs. Revenues Six Months Ended June 30, 2026 2025 Change Dx $ 5,662.8 $ 5,378.4 5.3 % BLS 1,616.8 1,506.1 7.3 % Intercompany eliminations and other (10.9) (12.1) (11.2) % Total $ 7,268.7 $ 6,872.4 5.8 % Dx revenues for the six months ended June 30, 2026, were $5,662.8, an increase of 5.3% over $5,378.4 during the six months ended June 30, 2025. The increase was due to organic revenue of 3.2%, acquisitions, net of divestitures, of 2.0%, and favorable foreign currency translation of 0.1%. 28 TABLE OF CONTENTS Dx total volume, measured by requisitions, increased by 2.8% as organic volume increased by 1.4% and acquisition volume, net of divestitures, contributed 1.3%. Price/mix increased by 2.5% due to organic growth of 1.8%, acquisitions, net of divestitures, of 0.6%, and favorable foreign currency translation of 0.1%. BLS revenues for the six months ended June 30, 2026, were $1,616.8, an increase of 7.3% over $1,506.1 during the six months ended June 30, 2025. The increase was due to organic growth of 5.0% and favorable foreign currency translation of 3.6%, partially offset by an unfavorable impact related to strategic actions undertaken in ED of 1.2%. Cost of Revenues Six Months Ended June 30, 2026 2025 Change Cost of revenues $ 5,142.9 $ 4,878.2 5.4 % Cost of revenues as a % of revenues 70.8 % 71.0 % Cost of revenues increased 5.4% during the six months ended June 30, 2026, as compared with the corresponding period in 2025. Cost of revenues as a percentage of revenues during the six months ended June 30, 2026, decreased to 70.8% as compared to 71.0% in the corresponding period in 2025. This decrease was primarily due to organic growth and operating efficiencies, partially offset by increased personnel costs. Selling, General, and Administrative Expenses Six Months Ended June 30, 2026 2025 Change SG&A $ 1,128.2 $ 1,125.3 0.3 % SG&A as a % of revenues 15.5 % 16.4 % SG&A as a percentage of revenues were 15.5% and 16.4% during the six months ended June 30, 2026, and 2025, respectively. The decrease was primarily due to revenue growth. Amortization of Intangibles and Other Assets Six Months Ended June 30, 2026 2025 Change Amortization of intangibles and other assets $ 153.7 $ 137.9 11.4 % The increase in amortization of intangibles and other assets primarily reflects additional amortization for assets acquired subsequent to June 30, 2025. Restructuring and Other Charges Six Months Ended June 30, 2026 2025 Change Restructuring and other charges $ 11.5 $ 10.5 10.5 % During the six months ended June 30, 2026, the Company recorded net restructuring and other charges of $11.5. The charges were comprised of $19.8 related to severance and other personnel costs, $3.3 in facility-related costs, and $0.1 in contract termination costs. The charges were adjusted by the reversal of a previously established liability of $8.4 in unused facility-related costs, $3.1 in unused contract termination costs, and $0.2 in unused severance and other personnel costs. During the six months ended June 30, 2025, the Company recorded net restructuring and other charges of $10.5. The charges were comprised of $17.0 related to severance and other personnel costs, $15.1 in contract termination costs, and $7.3 in facility-related costs. The charges were adjusted by the reversal of a previously established liability of $27.5 in unused facility-related costs and $1.4 in unused severance and other personnel costs. Interest Expense Six Months Ended June 30, 2026 2025 Change Interest expense $ 116.2 $ 113.1 2.7 % For the six months ended June 30, 2026, interest expense increased 2.7%, as compared with the corresponding period in 2025. The increase was primarily due to a higher average amount of total debt outstanding during the six months ended June 30, 2026, when compared to the six months ended June 30, 2025. 29 TABLE OF CONTENTS Equity Method Loss, Net Six Months Ended June 30, 2026 2025 Change Equity method loss, net $ (11.3) $ (2.0) 475.0 % Equity method loss, net represents the Company’s ownership share in joint venture partnerships along with equity investments in other companies in the healthcare industry. The increase in Equity method loss, net for the six months ended June 30, 2026, as compared with the corresponding period in 2025, was primarily due to the loss recognized from the SYNLAB investment. Other, net Six Months Ended June 30, 2026 2025 Change Other, net $ (16.6) $ (33.7) (50.7) % The change in Other, net for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025, was primarily due to investment losses of $8.6 recorded during the six months ended June 30, 2026, compared to investment losses of $34.7 for the corresponding period of 2025. In addition, there were foreign currency transaction losses of $7.5 recognized for the six months ended June 30, 2026, as compared to losses of $3.1 for the corresponding period of 2025. As the TSA between Fortrea and LCAH expired on June 30, 2025, there were no fees charged to Fortrea for the six months ended June 30, 2026, as compared to $3.8 in the corresponding period in 2025. Provision for Income Taxes Six Months Ended June 30, 2026 2025 Provision for income taxes $ 129.0 $ 128.6 Provision for income taxes as a percentage of earnings from operations before income taxes 18.3 % 22.2 % The decrease in the effective tax rate for the six months ended June 30, 2026, as compared to the corresponding period in 2025, was primarily attributable to discrete benefits recognized from the tax restructuring of certain foreign entities. Operating Income by Segment Six Months Ended June 30, 2026 2025 Change Dx segment operating income $ 981.3 $ 910.3 7.8 % Dx segment operating margin 17.3 % 16.9 % 0.4 % BLS segment operating income 262.9 230.2 14.2 % BLS segment operating margin 16.3 % 15.3 % 1.0 % Segment operating income 1,244.2 1,140.5 9.1 % General corporate and unallocated expenses (246.6) (271.6) (9.2) % Amortization of intangibles and other assets (153.7) (137.9) 11.4 % Restructuring and other charges (11.5) (10.5) 10.5 % Total Operating income $ 832.4 $ 720.5 15.5 % Dx segment operating income was $981.3 for the six months ended June 30, 2026, an increase of $71.0 over operating income of $910.3 in the corresponding period of 2025, and Dx segment operating margin increased approximately 40 basis points year-over-year. The increase in operating margin was primarily due to organic growth and operating efficiencies. BLS segment operating income was $262.9 for the six months ended June 30, 2026, an increase of $32.7 over operating income of $230.2 in the corresponding period of 2025, and BLS segment operating margin increased approximately 100 basis points year-over-year. The increase in operating margin was primarily due to organic growth in the Central Laboratory business and operating efficiencies from the strategic actions taken in ED. General corporate and unallocated expenses are comprised primarily of administrative services such as executive management, human resources, legal, finance, corporate affairs, and information technology. General corporate and unallocated expenses were $246.6 for the six months ended June 30, 2026, a decrease of $25.0 compared to general corporate and unallocated expenses of $271.6 in the corresponding period of 2025, primarily due to lower acquisition and disposition-related costs and LaunchPad costs. 30 TABLE OF CONTENTS LIQUIDITY AND CAPITAL RESOURCES (dollars and shares in millions, except per share amounts) The Company’s cash-generating capability and financial condition typically have provided ready access to capital markets. The Company’s principal source of liquidity is operating cash flow, supplemented by proceeds from debt offerings. The Company’s senior unsecured revolving credit facility is further discussed in Note 6 Debt to the Company’s Condensed Consolidated Financial Statements. In summary the Company’s cash flows were as follows: Six Months Ended June 30, 2026 2025 Net cash provided by operating activities $ 637.0 $ 639.1 Net cash used for investing activities (688.3) (430.1) Net cash used for financing activities (339.4) (1,107.1) Effect of exchange rate on changes in Cash and cash equivalents 0.2 26.7 Net decrease in Cash and cash equivalents $ (390.5) $ (871.4) Cash and cash equivalents at June 30, 2026, and 2025, totaled $141.8 and $647.3, respectively. Cash and cash equivalents consist of highly liquid instruments, such as time deposits, and other money market investments, which have original maturities of three months or less. In addition to Cash and cash equivalents, at June 30, 2026, the Company had $1,000.0 of available borrowings under its revolving credit facility, which, as amended on June 27, 2025, expires in 2030. Cash Flows from Operating Activities During the six months ended June 30, 2026, the Company’s operations provided $637.0 of cash as compared to $639.1 during the same period in 2025. The $2.1 decrease in net cash provided by operations during the six months ended June 30, 2026, as compared with the corresponding 2025 period, was primarily due to changes in net working capital, partially offset by higher cash earnings. Cash Flows from Investing Activities Net cash used for investing activities for the six months ended June 30, 2026, was $688.3 as compared to $430.1 for the six months ended June 30, 2025. The increase in cash used for investing activities for the six months ended June 30, 2026, as compared to the corresponding period in 2025, was primarily due to increased business acquisitions and capital expenditures, partially offset by a decrease in the purchase of equity affiliates and other investments. Capital expenditures were $252.6 and $203.9 for the six months ended June 30, 2026, and 2025, respectively. Capital expenditures for the six months ended June 30, 2026, were 3.5% of Revenues, primarily in connection with projects to support growth in the Company’s core businesses, facility expansion and updates, implement advanced technology, and further acquisition integration activities. Cash Flows from Financing Activities Net cash used for financing activities for the six months ended June 30, 2026, was $339.4 as compared to $1,107.1 for the six months ended June 30, 2025. The decrease in cash flows used for financing activities for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025, was primarily due to increased proceeds from the 2026 Term Loan of $750.0, decreased payments on senior notes of $500.0, increased Common Stock repurchases of $251.8, and decreased proceeds, net of repayments, from the Company’s AR Facility of $200.0. On January 28, 2026, the Company further amended its AR Facility. Among other things, this amendment extended the scheduled termination date to January 26, 2029. On March 20, 2026, the Company entered into the $750.0 2026 Term Loan that will mature on March 20, 2028. On June 1, 2026, the net proceeds of the 2026 Term Loan were used to redeem the Company’s outstanding 1.55% senior notes due 2026 and, to the extent not used for such purpose, were made available for other general corporate uses. The principal balance of the 2026 Term Loan bears interest at a floating per annum rate equal to, at the Company’s election, either (i) a SOFR-based rate plus a margin of 0.700% or (ii) a base rate plus a margin of 0.0%. Under the Company’s 2026 Term Loan, revolving credit facility, indentures relating to the Company’s senior notes, and AR Facility, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers, and with respect to the 2026 Term Loan and revolving credit facility, the Company is required to maintain certain leverage ratios. The Company was in compliance with all covenants at June 30, 2026, and expects 31 TABLE OF CONTENTS that it will remain in compliance with its existing debt covenants for the next 12 months. At June 30, 2026, the Company had outstanding authorization from its Board to purchase up to $378.6 maximum value of Common Stock. On July 8, 2026, the Board authorized the repurchase of an additional $1,000.0 in the maximum value of the Company’s shares of Common Stock as part of the Company’s ongoing share repurchase program, bringing the total share repurchase authorization to $1,378.6 maximum value of shares of Common Stock. The repurchase authorization has no expiration date. For the six months ended June 30, 2026, the Company paid $119.9 in Common Stock dividends. On July 9, 2026, the Company announced a cash dividend of $0.72 per share of Common Stock, or approximately $59.0 in the aggregate. The dividend will be paid on September 11, 2026, to stockholders of record of all issued and outstanding shares of Common Stock as of the close of business on August 28, 2026. The declaration and payment of any future dividends will be at the discretion of the Board. Guarantor Information In 2024, the Company, LCAH and U.S. Bank Trust Company, National Association (the Trustee) entered into a seventeenth supplemental indenture (the Seventeenth Supplemental Indenture) to the indenture, dated as of November 19, 2010, between LCAH and the Trustee (2010 Indenture). In addition, the Company, LCAH and the Trustee entered into the 2024 Indenture on September 23, 2024 (the 2024 Indenture, together with the 2010 Indenture, the Indentures). The Seventeenth Supplemental Indenture, among other things, provides for the full and unconditional guarantee by the Company of LCAH’s obligations under the 2010 Indenture, and each series of senior notes issued and outstanding thereunder, and the 2024 Indenture provides for the full and unconditional guarantee by the Company of LCAH’s obligations, and each series of senior notes issued and outstanding, thereunder (collectively, the Labcorp Holdings Guarantees). Also, the Indentures permit the Company to satisfy LCAH’s reporting obligations so long as the Labcorp Holdings Guarantees remain in place and the Company’s Condensed Consolidated Financial Statements and other information comply with the requirements of Rule 3-10 of Regulation S-X. At June 30, 2026, there was $2,593.1 and $2,000.0 aggregate principal amount of issued and outstanding senior notes of LCAH, issued under the 2010 Indenture and the 2024 Indenture, respectively, that are fully and unconditionally guaranteed by the Company. Accordingly, pursuant to Rule 3-10 of Regulation S-X, separate consolidated financial statements of LCAH have not been presented. As permitted under Rule 13-01(a)(4)(vi) of Regulation S-X, the Company has excluded the summarized financial information for LCAH because the assets, liabilities, and results of operations of LCAH are not materially different than the corresponding amounts in the Company’s Condensed Consolidated Financial Statements and management believes such summarized financial information would be repetitive and would not provide incremental value to investors. Credit Ratings The investment grade credit ratings from Moody’s and S&P Global Ratings contribute to the Company’s ability to access capital markets. Off-balance Sheet Arrangements The Company does not have any variable interest entities or special purpose entities whose financial results are not included in the Company’s Condensed Consolidated Financial Statements. The Company has a noncancelable contract with a vendor to purchase supplies inventory pursuant to which the Company is obligated to make expected total future minimum payments of $115.4, including $20.9 for the remainder of 2026, $20.5 in 2027, and $74.0 in 2028. Other Commercial Commitments The Company has debt instruments outstanding. At June 30, 2026, the Company had total future payments of $5,894.0, with $0.9 payable within 12 months. The Company has leases for PSCs, laboratories and testing facilities, clinical facilities, general office spaces, vehicles, and office and laboratory equipment. At June 30, 2026, the Company had total future lease payments for short-term and long-term leases of $1,098.9, with payments of $226.5 due within 12 months. On June 28, 2026, the Company entered into an agreement to acquire select assets of an outreach laboratory services business for a purchase price of approximately $155.0. The transaction is anticipated to close in the third quarter of 2026, subject to customary closing conditions and applicable regulatory approvals for a transaction of this type. At June 30, 2026, the Company had provided letters of credit aggregating approximately $107.4, primarily in connection with certain insurance programs which are renewed annually. 32 TABLE OF CONTENTS Based on current and projected levels of cash flows from operations, coupled with availability under its revolving credit facility and the 2026 Term Loan, the Company believes it has sufficient liquidity to meet both its anticipated short-term and long-term cash needs for the next 12 months and the reasonably foreseeable future; however, the Company continually reassesses its liquidity position in light of market conditions and other relevant factors. CRITICAL ACCOUNTING ESTIMATES There have been no material changes to the critical accounting estimates that appear in Part II. Item 7 of the Annual Report. IMPACT OF RECENT ACCOUNTING PRONOUNCEMENTS The impact of recent accounting pronouncements, if any, is discussed in Note 1 Basis of Financial Statement Presentation to the Condensed Consolidated Financial Statements.